Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenza Conteduca

Showing results (101-110 of 157) with videos related to

Pageof 16
Sort By:
Chinese Clinical Oncology|September 2, 2025
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative reviewFabrizio Di Costanzo, Iolanda Santa Parisi, Giuseppe Neola, et al.
The Oncologist|May 16, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancerVincenza Conteduca, Emanuela Scarpi, Alice Rossi, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
NPJ Precision Oncology|September 13, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastasesFrancesca Khani, William F Hooper, Xiaofei Wang, et al.
European Urology Oncology|June 22, 2025
Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer TreatmentUgo Giovanni Falagario, Francesco Pellegrino, Lars Björnebo, et al.
Clinical Genitourinary Cancer|July 19, 2024
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal CancerMarzia Del Re, Stefania Crucitta, Nicole Brighi, et al.
The Journal of Clinical Investigation|February 25, 2020
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerHimisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
Scientific Reports|July 2, 2025
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNAAlessandra Virga, Milena Urbini, Maurizio Polano, et al.
European Urology Oncology|July 11, 2025
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysisFabiano Flauto, Giuseppe Neola, Carmine Caso, et al.
Future Oncology (London, England)|September 13, 2018
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient ProgramFrancesca Maines, Ugo De Giorgi, Giuseppe Procopio, et al.
Pageof 16

Showing results (101-110 of 157) with videos related to

Sort By:
Pageof 16
Chinese Clinical Oncology|September 2, 2025
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative reviewFabrizio Di Costanzo, Iolanda Santa Parisi, Giuseppe Neola, et al.
The Oncologist|May 16, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancerVincenza Conteduca, Emanuela Scarpi, Alice Rossi, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
NPJ Precision Oncology|September 13, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastasesFrancesca Khani, William F Hooper, Xiaofei Wang, et al.
European Urology Oncology|June 22, 2025
Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer TreatmentUgo Giovanni Falagario, Francesco Pellegrino, Lars Björnebo, et al.
Clinical Genitourinary Cancer|July 19, 2024
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal CancerMarzia Del Re, Stefania Crucitta, Nicole Brighi, et al.
The Journal of Clinical Investigation|February 25, 2020
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerHimisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
Scientific Reports|July 2, 2025
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNAAlessandra Virga, Milena Urbini, Maurizio Polano, et al.
European Urology Oncology|July 11, 2025
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysisFabiano Flauto, Giuseppe Neola, Carmine Caso, et al.
Future Oncology (London, England)|September 13, 2018
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient ProgramFrancesca Maines, Ugo De Giorgi, Giuseppe Procopio, et al.
Pageof 16